| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.0076 | 0.9 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.0082 | 0.9 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | 0.0082 | 0.9 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | -0.045 | 0.9 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.0049 | 0.9 |